ClinicalTrials.gg
CompletedNCT05378269DARE-VVA1Updated Oct 21, 2024Results posted

Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA

A Phase 1/2 interventional study of Tamoxifen and Placebo in Vulvar Atrophy, sponsored by Daré Bioscience, Inc.. Completed at 2 sites in Australia. Open to female participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by Daré Bioscience, Inc. · Phase 1/2, Interventional, and Basic science

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2021, registered May 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
Female
01

Study summary

The purpose of the study is to study the safety, PK and PD of Intravaginal Tamoxifen on postmenopausal women with vulvar vaginal atrophy.

02

Conditions studied

  • Vulvar Atrophy
03

In context

Lead sponsor

Daré Bioscience, Inc. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Women aged 40-75 (inclusive).

      1. women with a between 18 and 34 kg/m2, inclusive.
      1. Postmenopausal, defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels > 40 mIU/mL or 6 weeks post-surgical bilateral oophorectomy.
      1. Have moderate to severe VVA as determined by self-assessment of the following symptoms (as none, mild, moderate, or severe), with at least 1 symptom reported as moderate or severe: vaginal dryness; vaginal and/or vulvar irritation/itching; dysuria; vaginal pain with sexual activity (dyspareunia); vaginal bleeding associated with sexual activity (presence versus absence).
      1. Women who currently have vaginal intercourse or other sexual activity (masturbation, etc.) at least once a month (with or without a partner), or who had intercourse or other sexual activity at least once a month in the past, but later decreased sexual activity due to excessive pain or vaginal dryness. Participants must be willing to engage in vaginal intercourse or other sexual activity (masturbation, etc.) at least 1 time between Days 49-56 of the clinical study.
      1. Participants, upon pelvic examination with speculum examination, must have a normal-appearing vulva other than atrophic changes, normal-appearing cervix other than atrophic changes (i.e., cervical stenosis and/or flushness with the vaginal wall) and normal-appearing vagina (without erosions, ulcerations, scarring, or evidence of dermatoses) other than atrophic changes (loss of ruggae, mucosal pallor, mucosal dryness, mucosal petechiae).
      1. Have an intact uterus and no prior history of endometrial ablation.
      1. Vaginal cellular cytology with ≤ 5% superficial cells.
      1. Vaginal pH > 5 at Screening Visit.
      1. Endometrial thickness ≤ 4 mm on transvaginal ultrasound.
      1. Current on all recommended screening and management requirements for cervical cancer.
      1. Normal mammogram report within 2 years of screening.
      1. Normal manual breast examination by investigator at baseline.
      1. Baseline hematology, clinical chemistry, urinalysis, /partial thromboplastin time (PT/PTT) and viral serologies for (HIV), virus (HCV), and surface antigen (HBsAg) all within normal limits OR accepted by the investigator and medical monitor as not .
      1. Normal 12-lead (ECG).
      1. Able to read, understand, and provide written and applicable data protection authorization after the nature of the study has been fully explained, and must be willing to comply with all study requirements.
      1. Willing and able to correctly and independently complete all study procedures.

Exclusion criteria

Exclusion Criteria:

  1. A history of or physical examination finding for any significant cardiovascular, renal, pulmonary, neurological and hepatic diseases preventing compliance with this study.
  2. A medical history of or use of anticoagulant drugs to treat or prevent coagulopathies, thrombophilia or thromboembolic disease (deep vein thrombosis, pulmonary or systemic embolism, stroke, or ).
  3. Uncontrolled hypertension (either systolic > 180 mmHg or diastolic > 105 mmHg), treatment with Class 1 antiarrhythmics or digitalis, history of congestive heart failure ( [NYHA] > Class I), or myocardial infarction within 12 months.
  4. Abnormal cervical screening test within 2 years of screening. Participant can have atypical squamous cells of undetermined significance if human papilloma virus-negative.
  5. History of or current endometrial pathology: hyperplasia, carcinoma and/or polyp (prior history of a benign endometrial polyp with no current evidence of polyp is acceptable).
  6. A medical history of breast cancer within 5 years of screening. Participants with a history of breast cancer more than 5 years prior to screening are considered eligible if their disease was node-negative, nonmetastatic, and if all treatment with aromatase inhibitors (AIs) or SERMs was completed at least 6 months prior to screening.
  7. A medical history of malignant melanoma.
  8. Any cancer (except nonmelanomatous skin cancer) diagnosed less than 5 years prior to the Screening Visit.
  9. A medical history of undiagnosed vaginal bleeding.
  10. A known or suspected estrogen-dependent neoplasia.
  11. Previous radiation treatment to the pelvis.
  12. Women who have previously reported an unsatisfactory outcome from a vaginal hormone therapy for VVA.
  13. Known to any ingredients in DARE-VVA1.
  14. Use of vaginal hormonal products (rings, creams, gels, tablets, capsules) within 4 weeks prior to Day 1.
  15. Use of transdermal estrogen or transdermal estrogen/progestin products within 4 weeks prior to Day 1.
  16. Use of oral estrogen and/or progestin therapy within 8 weeks prior to Day 1.
  17. Use of intrauterine progestin therapy within 8 weeks prior to Day 1.
  18. Use of progestin implants or estrogen-alone injectable drug therapy within 12 weeks prior to Day 1.
  19. Administration of estrogen pellet therapy or progestin injectable drug therapy within 6 months prior to Day 1.
  20. Use of thyroid hormone replacement therapy unless the participant is on a stable dose for > 6 months, and participant is euthyroid based on a normal, sensitive immunoassay for thyroid-stimulating hormone (TSH).
  21. Use of SERMs or AIs within 6 months prior to screening.
  22. Use of anabolic or other (including hormonal creams such as testosterone) within 4 weeks prior to Day 1.
  23. Use of corticosteroids, > 5 mg/day prednisone or equivalent, for more than 4 weeks within 4 weeks prior to Day 1.
  24. Participants with any self-reported active sexually transmitted disease and/or evidence of infection (including bacterial vaginosis) on vaginal examination by the investigator.
  25. Participants with a urinary tract infection during screening as assessed by urine dipstick test with abnormal test findings (any positive result for leukocytes AND any positive result for nitrites).
  26. Presence of uterine fibroids.
  27. Evidence of current alcohol or drug abuse in the past 60 days, including a positive result from the urine drugs of abuse or alcohol screen, or history of drug or alcohol dependence in the last 2 years, as assessed by the investigator. Alcohol abuse is defined as greater than 14 standard units/week for females, and drug abuse is defined as known psychiatric or substance abuse disorder that would interfere with participation with the requirements of this study, including current use of any illicit drugs. Use of medical cannabis is not exclusionary.
  28. Participation in any other drug or device trial in which administration of an investigational study drug/device occurred within 30 days or placement of a non-drug eluting medical device within 15 days prior to the Screening Visit (Visit 1).
  29. In the opinion of the investigator, participant has any disorder or finding that might interfere with the conduct of the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Vaginal insert

    Other: Placebo

  • Experimental
    DARE-VVA1 1mg

    vaginal insert

    Drug: Tamoxifen

  • Experimental
    DARE-VVA1 5mg

    vaginal insert

    Drug: Tamoxifen

  • Experimental
    DARE-VVA1 10mg

    vaginal insert

    Drug: Tamoxifen

  • Experimental
    DARE-VVA1 20mg

    vaginal insert

    Drug: Tamoxifen

Interventions

  • Tamoxifen vaginal insert

  • OtherPlacebo

    Placebo vaginal insert

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment Emergent Adverse Events

    to evaluate the safety and tolerability of DARE-VVA1 by intravaginal administration

    Time frame: 56 days

  2. Concentration of Tamoxifen in Serial Plasma Collections (Cmax)

    to determine the plasma concentrations of tamoxifen after intravaginal administration

    Time frame: 56 days

Secondary outcomes

  1. Evaluation of Vaginal Cytology

    to analyze the change from baseline to end of study of percentage of parabasal cells

    Time frame: 56 days

  2. Evaluation of Vaginal pH

    to analyze preliminary efficacy and pharmacodynamics of DARE-VVA1 by looking at change in baseline of vaginal pH from Day 1 to Day 56

    Time frame: 56 days

  3. Evaluation of Vaginal Cytology

    to analyze the change from baseline to end of study of percentage of superficial cells

    Time frame: 56 days

Other outcomes

  1. Collection of Menopause-specific Quality of Life (MENQOL) Questionnaire

    to analyze the impact of DARE-VVA1 on quality of life following treatment evaluated by total questionnaire score; looking for a decreased in total score.

    Time frame: 56 days

07

Results

Posted Oct 21, 2024
Limitations and caveats
The study enrollment proved difficult and lead to small numbers of subjects analyzed per arm.

Participant flow

Participant flow — Overall Study
MilestonePlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mg
Started43433
Completed33233
Not completed10200
Withdrew: Protocol violation10200

Outcome measures

PrimaryNumber of Subjects With Treatment Emergent Adverse Events

to evaluate the safety and tolerability of DARE-VVA1 by intravaginal administration

Time frame:
56 days
Reported as:
Count of participants · Participants
Number of Subjects With Treatment Emergent Adverse Events
ParticipantsPlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mg
Number of Subjects With Treatment Emergent Adverse Events32433
PrimaryConcentration of Tamoxifen in Serial Plasma Collections (Cmax)

to determine the plasma concentrations of tamoxifen after intravaginal administration

Time frame:
56 days
Reported as:
Geometric mean · ng/mL
Concentration of Tamoxifen in Serial Plasma Collections (Cmax)
ng/mLPlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mg
Concentration of Tamoxifen in Serial Plasma Collections (Cmax)0 ± 00.181 ± 32.211.93 ± 46.623.29 ± 12.015.50 ± 31.54
SecondaryEvaluation of Vaginal Cytology

to analyze the change from baseline to end of study of percentage of parabasal cells

Time frame:
56 days
Reported as:
Mean · % parabasal cells
Evaluation of Vaginal Cytology
% parabasal cellsPlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mg
Evaluation of Vaginal Cytology0 (0 to 0)-12.0 (-15 to -5)-22.5 (-45 to 0)-69.0 (-98 to -61)-94.0 (-100 to -04)
SecondaryEvaluation of Vaginal pH

to analyze preliminary efficacy and pharmacodynamics of DARE-VVA1 by looking at change in baseline of vaginal pH from Day 1 to Day 56

Time frame:
56 days
Reported as:
Mean · pH
Evaluation of Vaginal pH
pHPlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mg
Evaluation of Vaginal pH-0.3 ± 0.95-0.3 ± 0.31-0.3 ± 0.42-0.3 ± 0.70-0.7 ± 0.72
SecondaryEvaluation of Vaginal Cytology

to analyze the change from baseline to end of study of percentage of superficial cells

Time frame:
56 days
Reported as:
Mean · % superficial cells
Evaluation of Vaginal Cytology
% superficial cellsPlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mg
Evaluation of Vaginal Cytology0 (0 to 0)-3.0 (-4 to -2)8.5 (2 to 15)6.0 (1 to 14)52.3 (18 to 85)
Other pre-specifiedCollection of Menopause-specific Quality of Life (MENQOL) Questionnaire

to analyze the impact of DARE-VVA1 on quality of life following treatment evaluated by total questionnaire score; looking for a decreased in total score.

Time frame:
56 days

Results for this outcome have not been posted.

Adverse events

Collected over 56 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/4 (0%)0/4 (0%)3/4 (75%)
DARE-VVA1 1mg0/3 (0%)0/3 (0%)2/3 (66.7%)
DARE-VVA1 5mg0/4 (0%)0/4 (0%)4/4 (100%)
DARE-VVA1 10mg0/3 (0%)0/3 (0%)3/3 (100%)
DARE-VVA1 20mg0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Most frequent other events
EventPlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mg
HeadacheNervous system disorders2/41/32/41/31/3
DizzinessNervous system disorders2/40/31/40/30/3
Vulvovaginal discomfortReproductive system and breast disorders1/41/31/41/31/3
Vulvovaginal pruritisReproductive system and breast disorders1/41/30/41/31/3
Genital rashReproductive system and breast disorders0/41/30/40/30/3
Vulvovaginal erythemaReproductive system and breast disorders0/40/30/41/30/3
MigraineNervous system disorders0/41/30/40/30/3
Hot flushVascular disorders0/40/31/41/30/3
Postmenopausal hemorrhageReproductive system and breast disorders0/40/31/40/30/3
SciaticaNervous system disorders0/40/31/40/30/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mgTotal
<=18 years000000
Between 18 and 65 years3142212
>=65 years120115
Age, Continuous
Age, Continuous(years)PlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mgTotal
Mean61.3 ± 5.3865.7 ± 1.5359.3 ± 2.9957.7 ± 8.0861.3 ± 4.1660.9 ± 4.97
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mgTotal
Female4343317
Male000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mgTotal
Hispanic or Latino000000
Not Hispanic or Latino4343317
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mgTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White4343317
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)PlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mgTotal
Australia4343317
Body Mass Index
Body Mass Index(kg/m^2)PlaceboDARE-VVA1 1mgDARE-VVA1 5mgDARE-VVA1 10mgDARE-VVA1 20mgTotal
Mean25.03 ± 5.28726.04 ± 4.86926.58 ± 5.48624.67 ± 2.21923.70 ± 3.67625.27 ± 4.151
08

Study locations

2 sites
  • PARC Clinical Research
    Adelaide, Southern Australia 5000, Australia
  • Keogh Institute for Medical Research
    Nedlands, Western Australia 6009, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — A decision has not yet been made on when or what IPD to share when available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Dec 2022, 12 months.

Results were first posted in Oct 2024, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2022
First posted
May 18, 2022
StartActual
Nov 22, 2021
Primary completionActual
Dec 20, 2022
CompletionActual
Mar 1, 2023
Results first posted
Oct 21, 2024
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05378269
Lead sponsor
Daré Bioscience, Inc.
Responsible party
Sponsor
First posted
May 18, 2022
Start date
Nov 22, 2021
Primary completion
Dec 20, 2022
Completion
Mar 1, 2023
Results posted
Oct 21, 2024
Last update
Oct 21, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamoxifen

Start the discussion